Clinical trial · Interventional
Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer
NCT01333748CI-TRIAL-00007429EXSALcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine proportion of patients presented a search allelic imbalance of expression of genes BRCA 1 and 2 in population with hereditary breast and/or ovarian cancer risk and negative for deletion mutation BRCA 1 and 2 genes
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hereditary Breast and Ovarian Cancer Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood collection | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- patients group
- description
- Patients with ovarian and/or breast cancer
- interventionNames
- Genetic: blood collection
- type
- OTHER
- label
- control population
- description
- control population without history of breast and/or ovarian cancer
- interventionNames
- Genetic: blood collection
Primary outcomes (1)
- measure
- estimate the proportion of patients with allelic imbalance at the level of expression of BRCA1
- timeFrame
- blood sample at baseline, no follow-up in this study
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: For patients * Women with breast cancer and / or ovarian cancer meet criteria suggestive of a hereditary predisposition * Deleterious mutation of BRCA1 and BRCA2 sought and not highlighted * Age ≥ 18 years * Agreeing to participate in the study (a collection of signed informed consent) For control population * Women with no history of breast and / or ovarian cancer and no family history of breast and / or ovarian cancer among family members on the 1st and 2nd degree before age 50 for breast cancer and before 60 years for ovarian cancer * Agreeing to participate in the study (a collection of signed informed consent) Exclusion Criteria: For patients: * Patients with a known deleterious mutation in BRCA1 and BRCA2 * Patients do not meet criteria suggestive of a hereditary predisposition * Persons deprived of liberty or under guardianship (including guardianship) For control population: * Males * Personal or family history of breast and / or ovarian cancer (breast or ovarian cancer in their family experienced 1st and 2nd degree before age 50 for breast cancer before age 60 for cancer ovarian) * Persons deprived of liberty or under guardianship (including guardianship)
References
Publications (0)
Data not yet available
No reference posted for this study.